Sociedad Americana de Hirudoterapia

Ceftriaxone-Resistant Aeromonas hydrophila Infection Following Leech Therapy: A New Resistant Strain

Case report published in Annals of Plastic Surgery (2018)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportSeguridad y control de infeccionesBykowski MR, Zhu X, Diaz-Garcia R · Annals of plastic surgery, 2018

Abstract

We report a case of ceftriaxone-resistant Aeromonas hydrophila infection in a 32-year-old man after medicinal leech therapy. The patient underwent a free gracilis muscle flap for dorsal foot soft tissue reconstruction. Because of persistent congestion after venous revision, medicinal leech therapy was initiated to aid in flap salvage. Intravenous ceftriaxone was administered prior to application of leeches for prophylaxis against A. hydrophila. Leech therapy was discontinued after 1 week, and ceftriaxone was discontinued 24 hours thereafter. An infection developed despite being on appropriate antibiotics. Culture sensitivities indicated that A. hydrophila was resistant to ceftriaxone.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article
Indexed MeSH termsAdultAeromonas hydrophilaAnti-Bacterial AgentsCeftriaxoneDrug Resistance, BacterialGram-Negative Bacterial InfectionsHumansLeechingMaleMicrobial Sensitivity Tests

Resumen

First report of ceftriaxone-resistant Aeromonas hydrophila infection developing in a free gracilis flap patient despite ceftriaxone prophylaxis, expanding the spectrum of leech-associated resistant pathogens.

Por qué esto importa para la hirudoterapia

Documents evolving resistance patterns demanding updated antibiotic prophylaxis protocols for leech therapy.

Citación

Ceftriaxone-Resistant Aeromonas hydrophila Infection Following Leech Therapy: A New Resistant Strain.

Bykowski MR, Zhu X, Diaz-Garcia R · Annals of plastic surgery, 2018

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 26, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.